UK Housebuilding Sector: 2016 and beyond

Hardman & Co

Hardman & Co ReportIt was Arthur Holly Compton, a physicist and winner of the Nobel Prize in physics in 1927, who invented speed bumps; and they were first used in New Jersey in the US in 1906.

Widely employed now, this family of traffic calming devices uses vertical deflection to slow down motor vehicle traffic in order to improve safety conditions.

But they are not without their detractors and have been blamed for increased traffic noise/pollution, slower response times for emergency vehicles and, in Sweden, spinal stress in bus drivers.

Similarly, Brexit in the UK has its supporters and vilifiers, in almost equal measure, and on 23 June last year what should have been a jounce for the Housebuilders became something more seismic as the Sector subsequently lost 36% of its value.

This was more a speed wall than a bump (see chart overleaf) and although the Sector sedan drove carefully thereafter – there was still a 15% penalty in terms of value at the end of 2016.

It is also the case that the movement of share prices in most of Q3 and all of Q4 resembled an elongated speed bump warning sign i.e. velocity increased on positive news flow only to decelerate when it met the sleeping Brexit policemen.

But money has been made and more will be on offer as we expect this oscillation to continue; and in the first short trading week of the New Year, share prices rose 3.6% on average with three of them – Persimmon, Taylor Wimpey and Crest – up by 9 to 10%. Empirically, though, it is proven that driver selection and lap counting are critical.

Share on:

Latest Company News

Primary Health Properties surplus cash fuels generous dividend, Gervais Williams impressed

Gervais Williams highlights the benefits of long-dated, inflation-linked leases, fixed-rate debt, and synergies from the Assura acquisition, which he believes support resilient earnings, dividend growth, and balance sheet strength despite higher interest rates.

Watches of Switzerland Group upgrades FY26 outlook after strong Q3 performance

Watches of Switzerland Group PLC delivered strong Q3 FY26 performance, with sales growth ahead of expectations across both the US and UK and particularly robust Holiday trading.

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes.

SSE Plc Q3 Trading Update: EPS Guidance Maintained

SSE plc reports strong Q3 performance for the nine months to 31 December 2025, with a 64% increase in regulated networks investment and renewable output up 7% year on year.

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV.

DCC Plc reports strong Q3 growth and maintains FY outlook

DCC plc reported strong adjusted operating profit growth in the third quarter ended 31 December 2025, driven by good organic performance and the first contribution from recent acquisitions.

    Search

    Search